Paste your Google Webmaster Tools verification code here

May 2015

May 2015

Why Daiichi Sankyo had to offload Ranbaxy?

Read in this issue, why Daiichi Sankyo, the Japanese firm had to offload Ranbaxy which it had acquired eight years back with a hope to expand its business and secure its position in the world market even after the patent expiry of it's most famous drugs. Grab your copy to find out more!

Biotecnika bureau had a chance to interact with Ms. Anu Acharya, CEO, Mapmygenome on her entrepreneurial voyage and Dr. Anurag Mathur, Lead author, “Heart-on-chip” on his recent research.

Also read in the issue:

  • Are we amid a biotech bubble
  • Is it time to kill your R&D project?
  • India succumbs to H1N1
  • Top 10 GM crop supporting countries

Description

The Indian biotech sector faced a major turn of events when Daiichi Sankyo, Japanese firm whose hide and seek with Indian drug company Ranbaxy came to an end as it decided to sell off its entire holding of  Sun Pharmaceutical Industries and exit Indian pharma sector after a struggle of eight years. Why it had to offload Ranbaxy and what is in store with the company’s future businesses, find out in Biotecnika magazine’s May 2015 issue.

Features
  • BioNews
  • Rasayanika Zone
  • BioEvents
  • Readers Corner
  • & much more

subs   subs-online

Most Recent Entries

  • April 2016

    April 2016

  • March 2016

    March 2016

  • February 2016

    February 2016

  • January 2016

    January 2016

2014 Powered By Wordpress, Goodnews Theme By Momizat Team